MedPath

Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy

Phase 3
Completed
Conditions
Cardiovascular Diseases
Interventions
Registration Number
NCT00352183
Lead Sponsor
Solvay Pharmaceuticals
Brief Summary

Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to evaluate the efficacy and safety of combining fenofibrate and simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
450
Inclusion Criteria
  • Mixed dyslipidemia
Exclusion Criteria
  • Diabetes,
  • Known hypersensitivity to fenofibrate or simvastatin,
  • Pregnant or lactating women,
  • Contra-indication to fenofibrate or simvastatin,
  • Unstable or severe cardiac disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1Fenofibrate/Simvastatin-
2Simvastatin-
Primary Outcome Measures
NameTimeMethod
Triglycerides12 weeks
Percent change from baseline to 12 weeks of treatment in HDL-C12 weeks
Percent change from baseline to 12 weeks of treatment in LDL-C12 weeks
Secondary Outcome Measures
NameTimeMethod
Percent change from baseline to 24 weeks of treatment in Triglycerides24 weeks
Percent change from baseline to 24 weeks of treatment in HDL-C24 weeks
Percent change from baseline to 24 weeks of treatment in LDL-C24 weeks

Trial Locations

Locations (67)

Site 508

🇱🇹

Palanga, Lithuania

Site 506

🇱🇹

Kaunas, Lithuania

Site 204

🇦🇺

Adelaide, Australia

Site 109

🇳🇿

Takapuna, Auckland, New Zealand

Site 225

🇦🇺

Ingleburn, Australia

Site 207

🇦🇺

Brisbane, Australia

Site 505

🇱🇹

Klaipeda, Lithuania

Site 507

🇱🇹

Klaipeda, Lithuania

Site 504

🇱🇹

Siauliai, Lithuania

Site 103

🇳🇿

Auckland, New Zealand

Site 108

🇳🇿

Dunedin, New Zealand

Site 111

🇳🇿

Hastings, New Zealand

Site 101

🇳🇿

Christchurch, New Zealand

Site 501

🇱🇹

Vilnius, Lithuania

Site 208

🇦🇺

Brisbane, Australia

Site 105

🇳🇿

Tauranga, New Zealand

Site 102

🇳🇿

Auckland, New Zealand

Site 110

🇳🇿

Newtown, Wellington, New Zealand

Site 104

🇳🇿

Hamilton, New Zealand

Site 106

🇳🇿

Nelson, New Zealand

Site 203

🇦🇺

Bendigo, Australia

Site 212

🇦🇺

Elizabeth Vale, Australia

Site 220

🇦🇺

Coffs Harbour, Australia

Site 217

🇦🇺

Fitzroy, Australia

Site 214

🇦🇺

Adelaide, Australia

Site 218

🇦🇺

Daw Park, Australia

Site 201

🇦🇺

Camperdown, Australia

Site 221

🇦🇺

Brisbane, Australia

Site 202

🇦🇺

Burnie, Australia

Site 222

🇦🇺

Fremantle, Australia

Site 216

🇦🇺

Geelong, Australia

Site 213

🇦🇺

Kippa-ring, Australia

Site 211

🇦🇺

Meadowbrook, Australia

Site 209

🇦🇺

Launceston, Australia

Site 219

🇦🇺

Liverpool, Australia

Site 224

🇦🇺

Miranda, Australia

Site 205

🇦🇺

Parkville, Australia

Site 215

🇦🇺

Sydney, Australia

Site 301

🇪🇪

Tallinn, Estonia

Site 223

🇦🇺

Malvern, Australia

Site 302

🇪🇪

Tallinn, Estonia

Site 210

🇦🇺

Nambour, Australia

Site 305

🇪🇪

Tallinn, Estonia

Site 206

🇦🇺

Sale, Australia

Site 306

🇪🇪

Tallinn, Estonia

Site 303

🇪🇪

Tallinn, Estonia

Site 603

🇭🇺

Balatonfured, Hungary

Site 609

🇭🇺

Kecskemet, Hungary

Site 605

🇭🇺

Budapest, Hungary

Site 608

🇭🇺

Budapest, Hungary

Site 304

🇪🇪

Tartu, Estonia

Site 307

🇪🇪

Tartu, Estonia

Site 604

🇭🇺

Gyongyos, Hungary

Site 607

🇭🇺

Sopron, Hungary

Site 602

🇭🇺

Gyor, Hungary

Site 610

🇭🇺

Hodmezovasarhely, Hungary

Site 601

🇭🇺

Miskolc, Hungary

Site 606

🇭🇺

Szekesfehervar, Hungary

Site 406

🇱🇻

Jekabpils, Latvia

Site 404

🇱🇻

Tukums, Latvia

Site 403

🇱🇻

Daugavpils, Latvia

Site 401

🇱🇻

Ogre, Latvia

Site 405

🇱🇻

Riga, Latvia

Site 503

🇱🇹

Kaunas, Lithuania

Site 502

🇱🇹

Alytus, Lithuania

Site 402

🇱🇻

Riga, Latvia

Site 107

🇳🇿

Blenheim, New Zealand

© Copyright 2025. All Rights Reserved by MedPath